World Orphan Drug Congress USA focusses on the most pressing challenges and opportunities to bring rare disease therapies to patients faster.
Walter Colasante, Vice President in the Life Sciences Practice, will be speaking on “Value assessment is different for Rare Diseases, requiring new thinking to build consensus around access decisions” and Charles River Associates is a silver sponsor at this year’s conference.
For more information on this event, click here.
Disparities in screening and diagnosis for triple negative breast cancer
Gilead Sciences asked Charles River Associates and Tigerlily Foundation to examine the extent to which policies associated with triple negative breast cancer...